Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Authors' conclusion
Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year.
Study context
- Population
- Patients with HFpEF, BMI ≥30 and T2DM
- Participants
- 616 patients
- Comparison
- Semaglutide vs placebo
- Primary endpoint
- Change from baseline in KCCQ-CSS (0–100, higher = fewer symptoms and physical limitations) and change in body weight
- Follow-up
- 52 weeks
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Semaglutide
- Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) mean change
- 13.7 points
- Body weight mean % change
- −9.8%
Placebo
- KCCQ-CSS mean change
- 6.4 points
- Body weight mean % change
- −3.4%
Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) mean change
Semaglutide13.7 points
Placebo6.4 points
Body weight mean % change
Semaglutide−9.8%
Placebo−3.4%
Semaglutide vs PlaceboEstimated difference, points (95% CI)P value
KCCQ-CSS
7.3(4.1–10.4)
P < 0.001Semaglutide vs PlaceboEstimated difference, percentage points (95% CI)P value
Body weight
−6.4(−7.6 to −5.2)
P < 0.001Secondary outcomes
| Outcome | Estimated between-group difference (m) (95% CI) | P value | |
|---|---|---|---|
| Change in 6-minute walk distance (confirmatory secondary) | 14.3 (3.7–24.9) | P = 0.008 | |
| −100102030Difference, m (linear scale) |
| Outcome | Win ratio (95% CI) | P value | |
|---|---|---|---|
| Hierarchical composite (death, HF events, KCCQ-CSS and 6-minute walk distance change) | 1.58 (1.29–1.94) | P < 0.001 | |
| 0.512Win ratio (log scale) |
| Outcome | Estimated treatment ratio (95% CI) | P value | |
|---|---|---|---|
| Change in CRP level | 0.67 (0.55–0.80) | P < 0.001 | |
| 0.512Estimated treatment ratio (log scale) |
Safety
Serious adverse events
Original publication
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. Published 6 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →